跳到主要內容

Berger Franklin M 的 Form 4/A 修正申報

修正

Atea Pharmaceuticals, Inc.AVIR,2025/1/17 申報

申報編號
0000950170-25-006589
申報時間
2025/1/17
交易日
2025/1/15-1/16
申報延遲
2 天
10b5-1 計畫
沒有勾選
原始申報日
2025/1/17

這份申報列了 2 筆非衍生性交易。公開市場買進合計 $8.14 萬。交易後 2 天申報。

這份修正申報取代了 0000950170-25-006489(2025/1/17 申報)。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Berger Franklin MCIK 0001273885董事

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2025/1/15Common StockP買進取得+15,000$3.19F2+$47,850466,897直接
2025/1/16Common StockP買進取得+10,000$3.36F3+$33,600476,897直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

This Form 4/A has been filed solely to change the code reported in Column 4 of Table I of the Reporting Person's Form 4 filed on January 17, 2025, which had inadvertently noted a "D" instead of "A" to reflect an acquisition of the common stock of Atea Pharmaceuticals, Inc. (the "Company"), due to an administrative error.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.165 to $3.21. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F3

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.405. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)